Home
>
US Stocks
>
Curis Inc
Curis Inc
CRIS

Curis Inc (CRIS)

$6.635.96%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$6.73
Today Low/High$6.6 / $6.82
52 Week Low/High$1.06 / $17.4
P/E ratio-15.1
Market Cap$645.75M

Company Details

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
OrganisationCuris Inc
HeadquatersLexington, Massachusetts, US
Employees28
IndustryHealth Technology
CEOJames Dentzer

Discover more

Frequently Asked Questions

What is Curis Inc (CRIS) share price today?

Can Indians buy Curis Inc (CRIS) shares?

How can I buy Curis Inc (CRIS) shares from India?

Can Fractional shares of Curis Inc (CRIS) be purchased?

What are the documents required to start investing in Curis Inc (CRIS) stocks?

We are a SEBI registered investement advisor